Neuroprotective and acetylcholinesterase inhibitory activity of plumbagin in ICV-LPS induced behavioral deficits in rats

Ashok Jangra,Vaishali Chadha,Dinesh Kumar,Vipin Kumar,Mandeep K Arora
DOI: https://doi.org/10.1016/j.crbeha.2021.100060
2021-11-01
Current Research in Behavioral Sciences
Abstract:Plumbagin (5‑hydroxy-2-methyl-1,4-naphthoquinone), a phytoconstituent has been shown to exhibit potent antioxidant and anti-inflammatory effects. In the present investigation, we explored the neuroprotective effects of plumbagin against intracerebroventricular (ICV) lipopolysaccharide (LPS)-induced behavioral deficits. We found that ICV administration of LPS (5 μg/5μl in each ICV injection) bilaterally in the hippocampus caused significant reduction in learning and memory abilities of rats. Moreover, ICV-LPS treated rats displayed anxiety-like behavior evident by open field test and elevated plus maze test. Biochemical analysis in the hippocampus revealed oxidative-nitrosative stress, mitochondrial complexes (I, II, and III) impairment and cholinergic dysfunction in ICV-LPS rats. However, pre- and post-treatment with plumbagin (10 and 20 mg/kg) dose-dependently attenuated ICV-LPS induced oxidative stress (reduction of MDA and nitrite with GSH elevation), mitochondrial impairment, and cholinergic dysfunction (reduction of AChE) in the hippocampus. The pro-inflammatory cytokine (IL-1β) was also found to be increased in the ICV-LPS treated group which was markedly reduced by the treatment of Plumbagin-20 mg/kg. Further, in-silico analysis revealed that the calculated dock score (-5.116 kcal/mol) and predicted binding energy (-45.800 kcal/mol) supports the binding of plumbagin in the binding site of AChE. All these findings support the neuroprotective effect of plumbagin against ICV-LPS induced behavioral and neurochemical deficits in rats. Thus, plumbagin may be considered an intriguing pharmacological intervention for the management of behavioral dysfunction.
What problem does this paper attempt to address?